Results 291 to 300 of about 3,383,416 (397)

Retraction notice to "Effects of commonly used food additives on haematological parameters of Wistar rats" [Heliyon 6 (2020) e05221]. [PDF]

open access: yesHeliyon
Femi-Oloye OP   +12 more
europepmc   +1 more source

Clinical Practice Guideline for Evaluation and Management of Peripheral Nervous System Manifestations in Sjögren's Disease

open access: yesArthritis Care &Research, Accepted Article.
Objectives Sjögren's disease is an autoimmune disorder that can impact multiple organ systems, including the peripheral nervous system (PNS). PNS manifestations, which can exist concurrently, include mononeuropathies, polyneuropathies, and autonomic nervous system neuropathies. To help patients and providers in the decision‐making process, we developed
Anahita Deboo   +19 more
wiley   +1 more source

Unveiling insights from the Joint FAO/WHO Expert Committee on Food Additives (JECFA) portal. [PDF]

open access: yesSci Data
Ocagli H   +8 more
europepmc   +1 more source

Addressing Economic Insecurities Can Improve Patient‐Reported Outcomes in Lupus

open access: yesArthritis Care &Research, Accepted Article.
Background Economic insecurities, such as food, housing, transportation, and financial challenges, are modifiable risk factors and influence patient‐reported outcomes (PROs) in systemic lupus erythematosus (SLE). We examined: 1) associations between economic insecurities and PROs; 2) the impact of screening and addressing economic insecurities during ...
Jay Patel   +8 more
wiley   +1 more source

Re-evaluation of saccharin and its sodium, potassium and calcium salts (E 954) as food additives. [PDF]

open access: yesEFSA J
EFSA Panel on Food Additives and Flavourings (FAF)   +42 more
europepmc   +1 more source

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug

open access: yesArthritis Care &Research, EarlyView.
Objective We assessed the effectiveness of PrismRA to improve clinical outcomes among patients with rheumatoid arthritis (RA) initiating treatment with a biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD). Methods PrismRA incorporated 19 gene expression features and four clinical features to assess a patient's likelihood of
Fenglong Xie   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy